Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.
Sign Up to like & getrecommendations! Published in 2018 at "Inflammatory bowel diseases"
DOI: 10.1093/ibd/izx092
Abstract: The introduction of biosimilars with similar efficacy and safety to the reference drug allows for more cost-effective treatment options for patients with inflammatory bowel disease (IBD).1 Infliximab (originator), marketed under the name of Remicade (RMC),… read more here.
Keywords: inflammatory bowel; rmc p13; gastroenterology; p13 ... See more keywords